Loading organizations...
§ Private Profile · Chengdu, Sichuan, China
Biopharmaceutical company developing small molecule drugs and APIs for oncology, pain, and CNS disorders.
Hyperway Pharmaceutical is a biopharmaceutical R&D company based in Chengdu, Sichuan, China, developing innovative small molecule drugs and high-end active pharmaceutical ingredients (APIs) with a focus on oncology, pain management, and central nervous system disorders. The company has raised over RMB 100 million (approximately $14 million USD) across three financing rounds and filed over 70 patent applications globally. Its pipeline includes 11 Preliminary Clinical Candidates (PCCs) and 5 innovative drug projects in clinical trials, including a KRAS inhibitor project in Phase 1/2 development as of September 2024. Lead investors include Orinno Capital, Guoyuan Innovating Investment, Sunbow Capital, and Hygeia Capital. Hyperway Pharmaceutical was founded in January 2019 by Dr. Li Yingfu, who previously held senior positions at Bayer and Yangtze River Pharmaceutical.
Hyperway Pharm has raised $13.8M across 1 funding round.
Hyperway Pharm has raised $13.8M in total across 1 funding round.
Hyperway Pharm has raised $13.8M in total across 1 funding round.
Hyperway Pharm's investors include Wan Lei, Ziyuan Capital.
Hyperway Pharm has raised $13.8M across 1 funding round. Most recently, it raised $13.8M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 22, 2024 | $13.8M Series A | — | WAN LEI, Ziyuan Capital | Announced |